- This historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy and generates elevated and sustained factor IX ...
Dear ANCA‑associated vasculitis community, We are writing to share an important update on TAVNEOS® (avacopan) in the European Union (EU). The European Medicines Agency’s (EMA’s) Committee for ...
We are writing to share an important update on the availability of HEMGENIX ® (etranacogene dezaparvovec-drlb). CSL is currently experiencing a temporary global stockout of HEMGENIX ® that will result ...
ST. GALLEN, SWITZERLAND – 26 June 2026 Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...
Summit, New Jersey, USA | 21 October, 2025 – CSL Seqirus, a global leader in seasonal influenza prevention (ASX: CSL), has shared new actionable real-world evidence (RWE) reinforcing the critical role ...
ST. GALLEN, Switzerland and SAN DIEGO, April 29, 2025 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) are pleased to announce that the European Commission has approved the ...
Australia’s newest biotech incubator Jumar Bioincubator has officially opened its doors and revealed the first 16 innovative early-stage ventures to take up residency in its much-awaited ...
CSL Seqirus has today announced that construction of its new state-of-the-art manufacturing facility in Australia has reached its highest point, known as ‘topping out’. The world-class facility will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results